[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT07726238":3,"trial-entities:NCT07726238":89,"trial-summary:NCT07726238":92},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":9,"start_date":11,"sponsor_name":12,"lead_sponsor_class":13,"has_dmc":14,"brief_summary":15,"detailed_description":16,"conditions":17,"keywords":19,"study_type":22,"primary_purpose":23,"phases":24,"enrollment_info":26,"interventions":29,"primary_outcomes":41,"secondary_outcomes":46,"sex":55,"minimum_age":56,"maximum_age":57,"healthy_volunteers":58,"eligibility_criteria":59,"std_ages":73,"locations":76,"central_contacts":85,"overall_officials":86,"references":87,"see_also_links":88},"NCT07726238","NOBO105C01","A Third Proof-of-Concept Study to Evaluate the Efficacy of NOBO, a Novel Postbiotic, in Controlling Axillary Odor in Healthy Adults","A Randomized, Double-Blind, Placebo-Controlled, Split-Axilla, Proof-of-Concept Study #3 to Evaluate the Efficacy of NOBO, a Novel Postbiotic, in Controlling Axillary Odor in Healthy Adults","ACTIVE_NOT_RECRUITING","2026-07-31","2026-07","2026-07-27","Kingdom","INDUSTRY",false,"The goal of this clinical trial is to evaluate the performance of NOBO, a yeast-based fermentation product (postbiotic) designed to control axillary odor, in controlling axillary odor in healthy male and female adults age 18 - 70 with confirmed self-perception of body odor. The main question it aims to answer is: Does NOBO decrease self-perceived odor of the intervention axilla compared to the placebo axilla at any time point? Researchers will compare the intervention axilla odor score to the placebo axilla odor score to see if there is a difference in self-perceived odor. Participants will:\n\n* be given a NOBO deodorant spray and a placebo deodorant spray (each assigned to one axilla)\n* self assess body odor\n* self assess skin irritation","The study aims to evaluate the performance of NOBO, a yeast-based fermentate designed to control axillary odor, in controlling axillary odor. This third efficacy study of NOBO serves the purpose of validating the fermentate's efficacy and de-risking future external clinical studies.\n\nFor this study, a total of 14 subjects will be recruited based on the recruitment requirements. The target population for this study is healthy male and female adults age 18 - 70 with no existing skin conditions (e.g., eczema, psoriasis, contact dermatitis) and no known allergies to skin treatment products or cosmetics, toiletries, and\u002For topical drugs, with confirmed self-perception of body odor. All assessments are conducted via electronic surveys through an internal data collection platform.\n\nOn Day -1 to Day 0, each subject goes through a wash-in period with controlled washing with only unscented soap; no use of underarm product is allowed.\n\nParticipants are randomly assigned a treatment axilla: either left or right. One axilla (intervention axilla) will receive NOBO for the full duration of the intervention period. The other axilla (control axilla) will receive a placebo for the full duration of the study.\n\nThroughout the study, participants perform self-assessment of odor that includes assessing which axilla has stronger odor and rating the odor of each axilla using a standard odor rating scale (0-5). On Day 1 (AM) the subject performs the baseline self assessment of axillary odor and skin irritation. The subject then applies the deodorants to each axilla and self assesses odor immediately after the first application. On Day 1 (PM), \\~12 hours after Day 1 AM application, the subject self assesses odor and applies the deodorants to each axilla again. On Day 2 (AM), the subject applies the deodorant to each axilla. On Day 2 (PM), the subject self assesses odor and applies the deodorant to each axilla. On Day 3, no underarm washing is allowed. On Day 3 (AM), the subject applies the deodorant to each axilla. On Day 3 (PM), the subject self assesses odor and skin irritation on each axilla.\n\nObserving a decrease in self perceived odor of the intervention (NOBO) axilla compared to the placebo axilla at any post-baseline timepoin",[18],"Body Odor",[20,21],"Body odor","Deodorant","INTERVENTIONAL","TREATMENT",[25],"NA",{"count":27,"type":28},14,"ESTIMATED",[30,36],{"type":31,"name":32,"description":33,"armGroupLabels":34},"OTHER","NOBO postbiotic","The active ingredient in the NOBO deodorant is a yeast-based fermentation product (postbiotic) of the Starmerella genus.",[35],"NOBO deodorant",{"type":31,"name":37,"description":38,"armGroupLabels":39},"Placebo","The placebo deodorant is composed of 10% ethanol in water",[40],"Placebo deodorant",[42],{"measure":43,"description":44,"timeFrame":45},"Axillary odor self assessment (comparative)","Comparative assessment is simply a measurement of which axilla (left or right) smells worse.","At baseline (before application), immediately after first application, Day 1 PM, Day 2 PM, and Day 3 PM",[47,51],{"measure":48,"description":49,"timeFrame":50},"Axillary odor self assessment (on a 0-5 scale)","A 0 on the odor scale corresponds to \"no axillary odor\"; a 5 corresponds to \"very strong axillary odor\"","at baseline (before application), immediately after first application, Day 1 PM, Day 2 PM, and Day 3 PM",{"measure":52,"description":53,"timeFrame":54},"Skin irritation (pain & redness) self assessment (0-4 Draize scale; 0-10 pain scale)","A 0 on the Draize scale corresponds to no redness\u002Fedema; a 4 on the Draize scale corresponds to severe redness\u002Fedema. On the 0-10 pain scale, 0 = No pain at all, 5 = Moderate pain, 10 =Severe or unbearable pain.","at baseline (before application) and Day 3 PM","ALL","18 Years","70 Years",true,{"inclusion":60,"exclusion":64,"raw_text":72},[61,62,63],"Age: The subject is an adult between 18 and 70 y.o.","Skin health: The subject has no active skin conditions or lesions in the axillary region and no existing skin conditions (e.g., eczema, psoriasis, contact dermatitis).","Skin allergies: The subject has no known allergies to skin treatment products or cosmetics, toiletries, and\u002For topical drugs.",[65,66,67,68,69,70,71],"Subject is pregnant, nursing, or planning to become pregnant in the next 6 months.","Subject is an insulin-dependent diabetic.","Subject has been diagnosed or treated for cancer in the past 5 years.","Subject is currently using or has not used in the past two weeks any systemic antibiotics.","Subject is currently using or used within the last month any topical medications, over-the-counter (OTC) or prescription products on the underarms.","Subject is currently taking or plans to take during the study any anti-inflammatory for a chronic condition (except 81 mg-Aspirin per day), immunosuppressant, antihistamine, or sedative medications (i.e. containing antihistamines like Tylenol PM, Nyquil, etc.).","Subject is currently participating in another underarm clinical trial. Subjects may participate in other studies as long as the same test sites are not used or are testing similar products.","Inclusion Criteria:\n\n* Age: The subject is an adult between 18 and 70 y.o.\n* Skin health: The subject has no active skin conditions or lesions in the axillary region and no existing skin conditions (e.g., eczema, psoriasis, contact dermatitis).\n* Skin allergies: The subject has no known allergies to skin treatment products or cosmetics, toiletries, and\u002For topical drugs.\n\nExclusion Criteria:\n\n* Subject is pregnant, nursing, or planning to become pregnant in the next 6 months.\n* Subject is an insulin-dependent diabetic.\n* Subject has been diagnosed or treated for cancer in the past 5 years.\n* Subject is currently using or has not used in the past two weeks any systemic antibiotics.\n* Subject is currently using or used within the last month any topical medications, over-the-counter (OTC) or prescription products on the underarms.\n* Subject is currently taking or plans to take during the study any anti-inflammatory for a chronic condition (except 81 mg-Aspirin per day), immunosuppressant, antihistamine, or sedative medications (i.e. containing antihistamines like Tylenol PM, Nyquil, etc.).\n* Subject is currently participating in another underarm clinical trial. Subjects may participate in other studies as long as the same test sites are not used or are testing similar products.",[74,75],"ADULT","OLDER_ADULT",[77],{"facility":12,"city":78,"state":79,"zip":80,"country":81,"geoPoint":82},"Brooklyn","New York","11205","United States",{"lat":83,"lon":84},40.6501,-73.94958,[],[],[],[],{"nct_id":4,"conditions":90,"biomarkers":91},[18],[],{"nct_id":4,"found":58,"summary":93,"prompt_version":103},{"design":94,"status":95,"heading":96,"summary":97,"follow_up":98,"word_count":99,"commitments":100,"compensation":101,"drugs_mentioned":102},"This is an interventional study with 14 participants. You will be randomly assigned to use NOBO on one underarm and a placebo on the other.","completed","NOBO Postbiotic for Axillary Odor","This study is testing a new product called NOBO, which is a yeast-based postbiotic (a beneficial product made by yeast). The goal is to see if NOBO can help control underarm (axillary) odor in healthy adults. Researchers will compare how well NOBO works against a placebo (an inactive spray) by having participants use each on a different underarm. You can join if you are between 18 and 70 years old, have healthy skin under your arms, and believe you have body odor. The study wants to find out if NOBO reduces your self-perceived odor compared to the placebo.","Your odor will be assessed at baseline, immediately after the first application, and then in the evenings of Day 1, Day 2, and Day 3.",98,"You will use NOBO and a placebo spray, and self-assess your body odor and skin irritation at specific times over a few days.","Not stated in the trial record.",[37],"v2"]